GlaxoSmithKline to make more clinical trial data available

10/11/2012 | Forbes · Reuters

GlaxoSmithKline announced plans to allow independent researchers to request and analyze raw clinical trial data. If the company's plan works, "they're going to advance science," says Yale University epidemiologist Dr. Harlan Krumholz. The transparency policy would apply to current trials and many that have been completed for approved and experimental drugs.

View Full Article in:

Forbes · Reuters

Published in Brief: